Acer Therapeutics (NASDAQ:ACER) issued its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10, MarketWatch Earnings reports.
Acer Therapeutics stock traded up $0.29 during midday trading on Friday, reaching $24.91. The company’s stock had a trading volume of 7,116 shares, compared to its average volume of 29,773. Acer Therapeutics has a 52-week low of $11.36 and a 52-week high of $34.10. The stock has a market cap of $242.20 million, a PE ratio of -6.49 and a beta of 2.75.
A number of brokerages recently weighed in on ACER. William Blair restated an “outperform” rating on shares of Acer Therapeutics in a research note on Tuesday, August 14th. ValuEngine upgraded Acer Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 15th. BidaskClub cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 19th. Finally, Raymond James upgraded Acer Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $31.00 to $46.00 in a research note on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $48.00.
TRADEMARK VIOLATION NOTICE: “Acer Therapeutics (ACER) Posts Earnings Results, Beats Expectations By $0.10 EPS” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://transcriptdaily.com/2018/11/10/acer-therapeutics-acer-posts-earnings-results-beats-expectations-by-0-10-eps.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.